PDCD1 and pulmonary tuberculosis: In another study, a patient with NSCLC who developed pulmonary tuberculosis during treatment with the anti-PD-1 agent nivolumab had a paradoxical response (PR) ten days after initiation of the anti-MTB treatment [132].